Nature Reviews Drug Discovery

Wrestling with the RAS cancer drug pipeline

Asher Mullard Apr 01, 2025 pp. 242-243 10.1038/d41573-025-00043-9

Top companies and drugs by sales in 2024

Paul Verdin Apr 01, 2025 pp. 240-240 10.1038/d41573-025-00049-3

Upcoming FDA approval decisions in Q2 2025

Andrew Shui-Jezierski Apr 01, 2025 pp. 241-241 10.1038/d41573-025-00050-w

Engineered nasal bacteria slide drugs into the brain

M. Teresa Villanueva Apr 01, 2025 pp. 247-247 10.1038/d41573-025-00048-4

Bluebird Bio’s cut-price sale highlights challenges for gene therapy field

Asher Mullard Apr 01, 2025 pp. 239-239 10.1038/d41573-025-00046-6

FDA approves CSF1R inhibitor for rare, non-cancerous joint tumours

Asher Mullard Apr 01, 2025 pp. 238-238 10.1038/d41573-025-00045-7

FDA approves MEK inhibitor for rare neurofibromas

Asher Mullard Apr 01, 2025 pp. 238-238 10.1038/d41573-025-00044-8

ASO targets DNA repair protein to combat Huntington disease

Katie Kingwell Apr 01, 2025 pp. 248-248 10.1038/d41573-025-00042-w

Induced proximity pushes beyond protein degraders, as first RIPTAC moves into the clinic

Asher Mullard Apr 01, 2025 pp. 235-237 10.1038/d41573-025-00037-7

Genetics opens new route to degrader discovery

Alex Eccleston Apr 01, 2025 pp. 248-248 10.1038/d41573-025-00040-y

Oral STING agonist inhibits tumour growth

Sarah Crunkhorn Apr 01, 2025 pp. 249-249 10.1038/d41573-025-00033-x

Adrenomedullin triggers insulin resistance

Sarah Crunkhorn Apr 01, 2025 pp. 249-249 10.1038/d41573-025-00032-y

A platform for personalized ASO therapeutics

Sarah Crunkhorn Apr 01, 2025 pp. 249-249 10.1038/d41573-025-00034-w

Reversing lysosomal dysfunction to treat PAH

Sarah Crunkhorn Apr 01, 2025 pp. 249-249 10.1038/d41573-025-00035-9

Androgen membrane receptor modulates muscle strength

Sarah Crunkhorn Apr 01, 2025 pp. 246-246 10.1038/d41573-025-00031-z

The multiple myeloma drug market

Julia L. M. Morris, Rachel M. Webster Apr 01, 2025 pp. 244-245 10.1038/d41573-025-00017-x

Enhancing immunity during ageing by targeting interactions within the tissue environment

Olivia V. Bracken, Roel P. H. De Maeyer, Arne N. Akbar Apr 01, 2025 pp. 300-315 10.1038/s41573-024-01126-9

Targeting mitophagy in neurodegenerative diseases

Odetta Antico, Paul W. Thompson, Nicholas T. Hertz et al. Apr 01, 2025 pp. 276-299 10.1038/s41573-024-01105-0

Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery

Paolo Conflitti, Edward Lyman, Mark S. P. Sansom et al. Apr 01, 2025 pp. 251-275 10.1038/s41573-024-01083-3

IRDiRC perspectives on the application of digital biomarkers in therapeutic development for rare diseases

Rajesh Krishna, Anneliene H. Jonker, Thomas Morel et al. Apr 01, 2025 pp. 233-234 10.1038/d41573-024-00196-z